Wall Street heavy hitters like Citadel Advisors have been boosting their stakes in Bristol-Myers Squibb of late. Should retail investors follow in their footsteps?
Digging into the balance sheet of two drugmaking powerhouses to see which may be a better investment.
After five successful label expansions in less than a year, the FDA finally issues a denial for this immuno-oncology superstar.
The FDA's approval of Empliciti could reshape second-line multiple myeloma treatment.
High-priced cancer drugs are increasingly being placed in the highest tiers of insurers' drug formularies.
Combining Opdivo with other medications for pancreatic cancer could offer new hope to patients.
These five companies can provide years of steady payouts for patient investors.
The Swiss are on the offensive against cancer.
Annual global cancer incidence rates are expected to rise by nearly 60% in the next 20 years, prompting drug developers to get creative in their fight against cancer.
This healthcare ETF outperformed the overall market this week. Lets break down why.